Key result
Management of excessively elevated INR involves warfarin withdrawal or oral vitamin K in the absence of bleeding, and addition of coagulation factors (FFP or PCC) for active bleeding or INR >10.
Why the study?
How should excessive anticoagulant effect due to vitamin K antagonists be managed?
How should excessive anticoagulant effect due to vitamin K antagonists be managed?
This review outlines standard strategies for managing excessive anticoagulation from vitamin K antagonists, emphasizing oral vitamin K for elevated INR and the addition of FFP or PCC for active bleeding or INR >10.
Supports standard VKA reversal protocols; leaves open need for prospective comparative trials.
Unexpectedly elevated INR values are commonly encountered in clinical practice. In the absence of bleeding, such values may be treated with either simple warfarin withdrawal or the administration of low doses of oral vitamin K. Oral vitamin K will more rapidly return the INR to the therapeutic reference interval; however, its impact on bleeding is unknown. If the INR is in excess of 10, most experts would recommend the administration of vitamin K and, in the case of active bleeding, additional administration of coagulation factors either in the form of fresh frozen plasma (FFP) or prothrombin complex concentrates (PCC). Coagulation factor replacement is required given the need to urgently correct the INR; however, vitamin K should not be forgotten since it is required to antagonize the effect of warfarin, preventing "rebound" anticoagulation after transfused coagulation factors are consumed. This paper will review the evidence supporting various treatment modalities and will provide suggestions for treatment. Future advances in this area will likely focus on evaluations of the relative merits of FFP and PCCs.
No takes yet. Share an insight, caveat, or question.
Dentali et al. (2008) conducted a review in Excessive anticoagulant effect due to vitamin K antagonists. Vitamin K, fresh frozen plasma (FFP), or prothrombin complex concentrates (PCC) was evaluated. Management of excessively elevated INR involves warfarin withdrawal or oral vitamin K in the absence of bleeding, and addition of coagulation factors (FFP or PCC) for active bleeding or INR >10.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: